Results 81 to 90 of about 136,011 (340)

Malignant ectomesenchymoma in children: The European pediatric Soft tissue sarcoma Study Group experience

Pediatric Blood &Cancer, Volume 70, Issue 2, February 2023., 2023
Abstract Malignant ectomesenchymoma (MEM) is an extremely rare soft tissue tumor typical of young children, currently included in the category of skeletal muscle malignancies and characterized by a neuroblastic component. This study describes a series of 10 patients prospectively registered in the European paediatric Soft tissue sarcoma Study Group ...
Giuseppe Maria Milano, Daniel Orbach, Michela Casanova, Pablo Berlanga, Reineke A. Schoot, Nadege Corradini, Bernadette Brennan, Gema L. Ramirez‐Villar, Lisa Lyngsie Hjalgrim, Max M. van Noesel, Rita Alaggio, Andrea Ferrari   +11 more
wiley   +1 more source

Reduced-Dose or Discontinuation of Bevacizumab Might Be Considered after Variceal Bleeding in Patients with Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab: Case Reports

Medicina
Background and Objectives: Variceal bleeding (VB) is the most concerning condition that is difficult to treat after atezolizumab/bevacizumab in patients with advanced hepatocellular carcinoma (HCC).
Kyeong-Min Yeom, Young-Gi Song, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim   +4 more
doaj   +1 more source

Bevacizumab increases the risk of anastomosis site leakage in metastatic colorectal cancer

Frontiers in Oncology, 2022
BackgroundBevacizumab is a humanized monoclonal antibody against vascular endothelial growth factor and is used in combination with first-line chemotherapy in the treatment of metastatic colorectal cancer.
Seijong Kim, Jung Kyong Shin, Yoonah Park, Jung Wook Huh, Hee Cheol Kim, Seong Hyeon Yun, Woo Yong Lee, Yong Beom Cho, Yong Beom Cho, Yong Beom Cho   +9 more
doaj   +1 more source

Predicting Ovarian Cancer Treatment Response in Histopathology using Hierarchical Vision Transformers and Multiple Instance Learning [PDF]

arXiv, 2023
For many patients, current ovarian cancer treatments offer limited clinical benefit. For some therapies, it is not possible to predict patients' responses, potentially exposing them to the adverse effects of treatment without any therapeutic benefit.
arxiv  

Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion [PDF]

, 2008
Purpose: To evaluate the effect of intravitreal bevacizumab (Avastin) injections on visual acuity (VA) and foveal retinal thickness in patients with macular oedema secondary to branch retinal vein occlusion.Methods: A prospective, non-comparative ...
Alge, C. S., Burger, J., Haritoglou, Christos, Kampik, Anselm, Kook, Daniel, Kreutzer, Thomas C., Kunze, C., Priglinger, Siegfried, Strauss, R., Wolf, A. H.   +9 more
core   +1 more source

Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.

Journal of Clinical Oncology, 2007
PURPOSE Colorectal cancer is the second leading cause of cancer mortality in the United States. Antiangiogenic therapy with bevacizumab combined with chemotherapy improves survival in previously untreated metastatic colorectal cancer.
B. Giantonio, P. Catalano, N. Meropol, P. O'dwyer, E. Mitchell, S. Alberts, M. Schwartz, A. Benson   +7 more
semanticscholar   +1 more source

Combining Bevacizumab with Endostatin Gets Better Antitumor Efficacy in Vivo 
in Lung Cancer Animal Model

Chinese Journal of Lung Cancer, 2013
Background and objective The aim of this study is to investigate difference of antiangiogenesis ablility and interaction about bevacizumab and endostatin in vivo in lung cancer animal model.
Niu NIU, Baolan LI, Chaoyang LIU, Ying HU, Xuebing LI, Jie LI, Heling SHI, Haiqing ZHANG   +7 more
doaj   +1 more source

Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study

BMC Cancer, 2011
Background We describe early dissemination patterns for first-line bevacizumab given for metastatic colorectal cancer treatment. Methods We analyzed patient surveys and medical records for a population-based cohort with metastatic colorectal cancer ...
Fouad Mona N, Weeks Jane C, Zullig Leah L, Kolimaga Jane T, Schrag Deborah, Abbott David H, Grambow Steven C, Malin Jennifer L, Zafar S Yousuf, Ayanian John Z, Wallace Robert, Kahn Katherine L, Ganz Patricia A, Catalano Paul, West Dee W, Provenzale Dawn   +15 more
doaj   +1 more source

Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated With Atezolizumab Plus Bevacizumab

Liver Cancer, 2022
Introduction: In the Phase 3 IMbrave150 trial (NCT03434379), atezolizumab + bevacizumab demonstrated a clinically meaningful survival benefit over sorafenib in patients with unresectable hepatocellular carcinoma (HCC), including those with hepatitis B ...
Chiun Hsu, Michel Ducreux, Andrew X. Zhu, Shukui Qin, Masafumi Ikeda, Tae-You Kim, Peter R. Galle, Richard S. Finn, Ethan Chen, Ning Ma, Youyou Hu, Lindong Li, Ann-Lii Cheng   +12 more
doaj   +1 more source

Multi-indication evidence synthesis in oncology health technology assessment [PDF]

arXiv, 2023
Background: Cancer drugs receive licensing extensions to include additional indications as trial evidence on treatment effectiveness accumulates. We investigate how sharing information across indications can strengthen the inferences supporting Health Technology Assessment (HTA).
arxiv